Edward Faught

ORCID: 0000-0001-7415-8044
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Epilepsy research and treatment
  • Pharmacological Effects and Toxicity Studies
  • Neuroscience and Neuropharmacology Research
  • Pharmaceutical studies and practices
  • EEG and Brain-Computer Interfaces
  • Diet and metabolism studies
  • Functional Brain Connectivity Studies
  • Advanced MRI Techniques and Applications
  • Acute Ischemic Stroke Management
  • Cerebrovascular and Carotid Artery Diseases
  • Metabolism and Genetic Disorders
  • Hemoglobinopathies and Related Disorders
  • Infectious Encephalopathies and Encephalitis
  • Bacterial Infections and Vaccines
  • Advanced NMR Techniques and Applications
  • Atomic and Subatomic Physics Research
  • Pharmaceutical Economics and Policy
  • Intracerebral and Subarachnoid Hemorrhage Research
  • Neurological disorders and treatments
  • Vagus Nerve Stimulation Research
  • Neurological and metabolic disorders
  • Cannabis and Cannabinoid Research
  • Neurological Complications and Syndromes
  • Intraocular Surgery and Lenses
  • Electroconvulsive Therapy Studies

Emory University
2010-2024

Emory and Henry College
2021

Emory University Hospital
2012-2016

Pfizer (United Kingdom)
2010

UCB Pharma (Belgium)
2010

Lundbeck (Germany)
2010

University of Alabama at Birmingham
1996-2008

Birmingham VA Medical Center
2008

Allen Institute for Brain Science
2007

Columbia University
2007

Background and Purpose —Medical neurological complications after acute ischemic stroke may adversely impact outcome in some cases be preventable. Limited data exist regarding the frequency of such occurring first days ictus relationship these to outcome. Our objective was identify types, severity, medical following determine their role mortality functional Methods —Rates serious (life-threatening) nonserious were derived from placebo limb Randomized Trial Tirilazad Mesylate Acute Stroke...

10.1161/01.str.29.2.447 article EN Stroke 1998-02-01

Abstract We studied 10 medically intractable temporal lobe epilepsy (TLE) patients prior to surgery using proton magnetic resonance spectroscopic imaging (MRSI) localize seizure foci. found significantly elevated creatine/ N ‐acetylaspartate (Cr/NAA) unilaterally in 8 and bilaterally 2 patients. Five have been again 1 year after surgery. In the with bilateral onsets, MRSI showed normalization of Cr/NAA unoperated contralateral tissue following surgical elimination seizures. This study...

10.1002/ana.410400215 article EN Annals of Neurology 1996-08-01

To study the impact of nonadherence to antiepileptic drugs (AEDs) on health care utilization and direct medical costs in a Medicaid population.A retrospective cohort design was employed using state claims data from Florida, Iowa, New Jersey during period January 1997 June 2006. Patients aged >or=18 years with one or more neurologist visit an epilepsy diagnosis two pharmacy for AEDs were included. Medication possession ratio (MPR) used evaluate AED adherence MPR >or= 0.80 considered adherent...

10.1111/j.1528-1167.2008.01794.x article EN Epilepsia 2008-10-06

Abstract We performed proton magnetic resonance spectroscopic imaging (MRSI) at high field (4.1 T) to study N ‐acetylaspartate, creatine, and choline levels in the brains of normal control subjects patients with intractable temporal lobe epilepsy. compared results MRSI those other presurgical techniques determine sensitivity this method lateralization epileptic focus. The hippocampal creatine— ‐acetylaspartate ratio was 0.71 ± 0.14 no differences between left right. Using mean plus 2...

10.1002/ana.410380309 article EN Annals of Neurology 1995-09-01

<b>Objective: </b> To investigate the association of an indicator hippocampal function with severity depression symptoms in temporal lobe epilepsy. <b>Methods: We evaluated 31 patients video/EEG-confirmed epilepsy using creatine/<i>N</i>-acetylaspartate ratio maps derived from a previously validated <sup>1</sup>H magnetic resonance spectroscopic imaging (<sup>1</sup>H-MRSI) technique at 4.1 T. also assessed symptoms, epilepsy-related factors, and self-perceived social vocational disability....

10.1212/01.wnl.0000252813.86812.81 article EN Neurology 2007-01-30

Abstract The diagnosis of epilepsy is associated with loss predictability, which invariably results in the fear when and if future seizures will occur. For a subset patients (PWE), there may be pathological persistent seizure occurrence, resulting limitations to daily activities through avoidant behaviors. Paradoxically, research anticipatory anxiety (AAS; also referred as phobia) has been practically nonexistent and, not surprisingly, this condition remains underrecognized by clinicians....

10.1002/epd2.20224 article EN cc-by-nc-nd Epileptic Disorders 2024-04-16

Prior research on the relationship between visual confrontation naming and hippocampal function has been inconclusive. The present study examined this using quantitative 1H magnetic resonance spectroscopy (1H-MRS) to operationalize of left right hippocampi. 60-item Boston Naming Test (BNT) was used measure naming. Our sample included 46 patients with medically intractable, focal mesial temporal lobe epilepsy who had screened for all pathology other than sclerosis. Statistics Pearson...

10.1093/brain/123.4.770 article EN Brain 2000-04-01

Summary: Purpose: To evaluate the tolerability and safety of gabapentin (GBP) as add‐on therapy for seizure control. Methods: Conducted in an outpatient setting reflecting usual practice, this study compared GBP dosages ≤1,800 versus &gt;1,800 mg/day, when these doses were required to achieve most effective Two analyses adverse events are presented: safety. In analysis, each patient served his or her own control compare occurrence at mg/day. The analysis patients receive least one dose have...

10.1111/j.1528-1157.1999.tb00804.x article EN Epilepsia 1999-07-01

The therapeutic efficacy of prostacyclin in nonhemorrhagic cerebral infarction was assessed a placebo-controlled double-blind trial. A total 80 patients with stroke onset within 24 hours were randomized into placebo (37 patients) and (43 groups. Demographic data risk factors comparable. Patients the group received continuous i.v. infusion at an average rate 8.5 ng/kg/min for 64 hours. vehicle only similar fashion. During treatment hemodynamic changes more prominent receiving included...

10.1161/01.str.18.2.352 article EN Stroke 1987-03-01

Because interictal temporal lobe delta activity (TLDA) has been described in 30 to 90% of patients with epilepsy (TLE) but not investigated extratemporal epilepsy, we sought determine the localizing significance TLDA. We compared presurgical scalp EEG results 47 consecutive who received resection (40 frontal and 7 parietal-occipital) for intractable 43 anterior lobectomy. defined lateralized TLDA as runs lower than 4-Hz waveforms that were easily distinguished from background rhythms maximal...

10.1212/wnl.52.1.202 article EN Neurology 1999-01-01

The efficacy and safety of felbamate monotherapy were evaluated in 52 patients with refractory partial seizures or without secondary generalization a double-blind, randomized, placebo-controlled trial. Each patient completed routine evaluation for epilepsy surgery was randomized to receive either felbamate, titrated maximum daily dose 3600 mg over 2 days, placebo during the 10-day, inpatient, treatment phase. An intent-to-treat analysis performed on data all who received study medication,...

10.1016/0920-1211(94)00084-a article EN cc-by-nc-nd Epilepsy Research 1995-03-01

Topiramate (TPM) is a widely-used drug for the treatment of epilepsy. It useful several types partial-onset and generalized-onset seizures, therefore considered broad-spectrum agent. also effective as prophylactic against migraine headaches. TPM was first approved prescription use in 1996. In various countries it now adjunctive monotherapy seizures therapy generalized tonic-clonic nonfocal origin, children adults. For initial new-onset target dose 100 mg/day adults recommended. Adjunctive...

10.2147/ndt.s512 article EN Neuropsychiatric Disease and Treatment 2008-01-01
Laura K. Lamberta Melissa M. Asmar Megan Fredwall Stephanie M. Ahrens Shasha Bai and 95 more Mariah Eisner Fred A. Lado Stephan Schuele Dave Clarke Ahmed Abdelmoity Kathryn A. Davis Jennifer L. Hopp Mohamad Z. Koubeissi Meriem K. Bensalem Owen Susan T. Herman Adam P. Ostendorf Aamr A. Herekar Ki Hyeong Lee N. Rodgers Mian Z. Urfy Marjorie Bunch James Valeriano Esmeralda Park Linda Laux Debopam Samanta Pradeep N. Modur S. W. Ricky Lee Jeffrey Politsky Yong Park Verónica Sosa Atul Syal Steven Chung David M. Labiner Alberto Pinzon-Ardila John Kerrigan Susan T. Herman Erasmo A. Passaro Sairam Atluri Paul C. Van Ness Sadat Shamim Andrew Zillgitt Daniel Arndt Bernard Chang Mary Ransom Phillip L. Pearl Georgia Montouris Samrina Hanif Jeffrey Politsky Aashit Shah Graham Huesmann Rajdeep Singh Ilona S. Humes Katherine C. Van Poppel Jeffrey M. Chung Timothy Feyma Marco Block Kathryn Polovitz Sanjay Singh Daniel Gossett Yaman Z. Ekşioğlu Kevin Chapman Deborah Holder Aimée F. Luat Michael Strunc Ahmed Abdelmoity John M. Schreiber Hema Patel Lily Tran J. H. Pollard Tracy A. Glauser Imad Najm Carl W. Bazil Daniel L. Weber Susan T. Arnold Megan Selvitelli William J. Bell Shefali Karkare Matthew Sweney Jennifer Madan Cohen Saleem Malik Melissa Carran Barbara C. Jobst Gogi Kumar Edward H. Maa Saurabh R. Sinha Edward Faught Jack H. Mendelson Adam P. Ostendorf Rolando Ania Guadalupe Fernandez Baca Vaca Sheri Cotterman-Hart Nathan B. Fountain Manoj Raghavan J. Alario Jeffrey Politsky Vibhangini S. Wasade Diosely C. Silveira David Millett Fred A. Lado Eduardo Locatelli

Status epilepticus (SE) is a neurologic emergency that requires urgent recognition and medical management. SE management remains heterogeneous across centers. We analyzed treatment protocols from level 3 4 epilepsy Discrete data including stabilization measures, timing of phases, medications, doses, routes administration were collected each protocol described using frequency for categorical variables median continuous variables. The distribution times dosing compared with the AES guideline....

10.1212/wnl.0000000000213689 article EN Neurology 2025-05-16
Coming Soon ...